|
1
|
Markowitz SD and Bertagnolli MM: Molecular
origins of cancer: Molecular basis of colorectal cancer. N Engl J
Med. 361:2449–2460. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bardhan K and Liu K: Epigenetics and
colorectal cancer pathogenesis. Cancers (Basel). 5:676–713. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lao VV and Grady WM: Epigenetics and
colorectal cancer. Nat Rev Gastroenterol Hepatol. 8:686–700. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hinoue T, Weisenberger DJ, Lange CP, Shen
H, Byun HM, Van Den Berg D, Malik S, Pan F, Noushmehr H, van Dijk
CM, et al: Genome-scale analysis of aberrant DNA methylation in
colorectal cancer. Genome Res. 22:271–282. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hellman A and Chess A: Gene body-specific
methylation on the active X chromosome. Science. 315:1141–1143.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jones PA: Functions of DNA methylation:
Islands, start sites, gene bodies and beyond. Nat Rev Genet.
13:484–492. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Herman JG and Baylin SB: Gene silencing in
cancer in association with promoter hypermethylation. N Engl J Med.
349:2042–2054. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang CJ, Zhou JX, Liu J, Ma ZY, Zhang SW,
Dou K, Huang HW, Cai T, Liu R, Zhu JK, et al: The splicing
machinery promotes RNA-directed DNA methylation and transcriptional
silencing in Arabidopsis. EMBO J. 32:1128–1140. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schwitalla S, Ziegler PK, Horst D, Becker
V, Kerle I, Begus-Nahrmann Y, Lechel A, Rudolph KL, Langer R,
Slotta-Huspenina J, et al: Loss of p53 in enterocytes generates an
inflammatory microenvironment enabling invasion and lymph node
metastasis of carcinogen-induced colorectal tumors. Cancer Cell.
23:93–106. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Amatu A, Sartore-Bianchi A, Moutinho C,
Belotti A, Bencardino K, Chirico G, Cassingena A, Rusconi F,
Esposito A, Nichelatti M, et al: Promoter CpG island
hypermethylation of the DNA repair enzyme MGMT predicts clinical
response to dacarbazine in a phase II study for metastatic
colorectal cancer. Clin Cancer Res. 19:2265–2272. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gay LJ, Mitrou PN, Keen J, Bowman R,
Naguib A, Cooke J, Kuhnle GG, Burns PA, Luben R, Lentjes M, et al:
Dietary, lifestyle and clinicopathological factors associated with
APC mutations and promoter methylation in colorectal cancers from
the EPIC-Norfolk study. J Pathol. 228:405–415. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rawson JB, Mrkonjic M, Daftary D, Dicks E,
Buchanan DD, Younghusband HB, Parfrey PS, Young JP, Pollett A,
Green RC, et al: Promoter methylation of Wnt5a is associated with
microsatellite instability and BRAF V600E mutation in two large
populations of colorectal cancer patients. Br J Cancer.
104:1906–1912. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nakagawa H, Nuovo GJ, Zervos EE, Martin EW
Jr, Salovaara R, Aaltonen LA and de la Chapelle A: Age-related
hypermethylation of the 5′ region of MLH1 in normal colonic mucosa
is associated with microsatellite-unstable colorectal cancer
development. Cancer Res. 61:6991–6995. 2001.PubMed/NCBI
|
|
14
|
Shima K, Nosho K, Baba Y, Cantor M,
Meyerhardt JA, Giovannucci EL, Fuchs CS and Ogino S: Prognostic
significance of CDKN2A (p16) promoter methylation and loss of
expression in 902 colorectal cancers: Cohort study and literature
review. Int J Cancer. 128:1080–1094. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Oliveira C, Velho S, Domingo E, Preto A,
Hofstra RM, Hamelin R, Yamamoto H, Seruca R and Schwartz S Jr:
Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur
preferentially in MSI sporadic colorectal cancer. Oncogene.
24:7630–7634. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Coppedè F: Epigenetic biomarkers of
colorectal cancer: Focus on DNA methylation. Cancer Lett.
342:238–247. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lu Y, Lemon W, Liu PY, Yi Y, Morrison C,
Yang P, Sun Z, Szoke J, Gerald WL, Watson M, et al: A gene
expression signature predicts survival of patients with stage I
non-small cell lung cancer. PLoS Med. 3:e4672006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Morishita H and Yagi T: Protocadherin
family: Diversity, structure, and function. Curr Opin Cell Biol.
19:584–592. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Stanislawska-Sachadyn A, Mitchell LE,
Woodside JV, Buckley PT, Kealey C, Young IS, Scott JM, Murray L,
Boreham CA, McNulty H, et al: The reduced folate carrier (SLC19A1)
c.80G>A polymorphism is associated with red cell folate
concentrations among women. Ann Hum Genet. 73:484–491. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang L, Zhang T, Xie C, Liao X, Yu Q,
Feng J, Ma H, Dai J, Li M, Chen J, et al: SLCO1B1 and SLC19A1 gene
variants and irinotecan-induced rapid response and survival: A
prospective multicenter pharmacogenetics study of metastatic
colorectal cancer. PLoS One. 8:e772232013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shaywitz AJ and Greenberg ME: CREB: A
stimulus-induced transcription factor activated by a diverse array
of extracellular signals. Annu Rev Biochem. 68:821–861. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Altarejos JY and Montminy M: CREB and the
CRTC co-activators: Sensors for hormonal and metabolic signals. Nat
Rev Mol Cell Biol. 12:141–151. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ionov Y, Matsui S and Cowell JK: A role
for p300/CREB binding protein genes in promoting cancer progression
in colon cancer cell lines with microsatellite instability. Proc
Natl Acad Sci USA. 101:1273–1278. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wickstrom SA, Masoumi KC, Khochbin S,
Fassler R and Massoumi R: CYLD negatively regulates cell-cycle
progression by inactivating HDAC6 and increasing the levels of
acetylated tubulin. EMBO J. 29:131–144. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
O'Donnell MA, Perez-Jimenez E, Oberst A,
Ng A, Massoumi R, Xavier R, Green DR and Ting AT: Caspase 8
inhibits programmed necrosis by processing CYLD. Nat Cell Biol.
13:1437–1442. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gao J, Sun L, Huo L, Liu M, Li D and Zhou
J: CYLD regulates angiogenesis by mediating vascular endothelial
cell migration. Blood. 115:4130–4137. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Alameda JP, Fernandez-Acenero MJ,
Moreno-Maldonado R, Navarro M, Quintana R, Page A, Ramirez A, Bravo
A and Casanova ML: CYLD regulates keratinocyte differentiation and
skin cancer progression in humans. Cell Death Dis. 2:e2082011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hellerbrand C, Bumes E, Bataille F,
Dietmaier W, Massoumi R and Bosserhoff AK: Reduced expression of
CYLD in human colon and hepatocellular carcinomas. Carcinogenesis.
28:21–27. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Taylor KH, Pena-Hernandez KE, Davis JW,
Arthur GL, Duff DJ, Shi H, Rahmatpanah FB, Sjahputera O and
Caldwell CW: Large-scale CpG methylation analysis identifies novel
candidate genes and reveals methylation hotspots in acute
lymphoblastic leukemia. Cancer Res. 67:2617–2625. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang R, Li WW, Hoang BH, Kim H, Banerjee
D, Kheradpour A, Healey JH, Meyers PA, Bertino JR and Gorlick R:
Quantitative correlation between promoter methylation and messenger
RNA levels of the reduced folate carrier. BMC Cancer. 8:1242008.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Demura M and Bulun SE: CpG dinucleotide
methylation of the CYP19 I.3/II promoter modulates cAMP-stimulated
aromatase activity. Mol Cell Endocrinol. 283:127–132. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Massoumi R, Kuphal S, Hellerbrand C, Haas
B, Wild P, Spruss T, Pfeifer A, Fassler R and Bosserhoff AK:
Down-regulation of CYLD expression by Snail promotes tumor
progression in malignant melanoma. J Exp Med. 206:221–232. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chiba T, Marusawa H and Ushijima T:
Inflammation-associated cancer development in digestive organs:
Mechanisms and roles for genetic and epigenetic modulation.
Gastroenterology. 143:550–563. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mossman D and Scott RJ: Long term
transcriptional reactivation of epigenetically silenced genes in
colorectal cancer cells requires DNA hypomethylation and histone
acetylation. PLoS One. 6:e231272011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lopez-Serra P and Esteller M: DNA
methylation-associated silencing of tumor-suppressor microRNAs in
cancer. Oncogene. 31:1609–1622. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
McGarvey KM, Greene E, Fahrner JA,
Jenuwein T and Baylin SB: DNA methylation and complete
transcriptional silencing of cancer genes persist after depletion
of EZH2. Cancer Res. 67:5097–5102. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lee BB, Lee EJ, Jung EH, Chun HK, Chang
DK, Song SY, Park J and Kim DH: Aberrant methylation of APC, MGMT,
RASSF2A, and Wif-1 genes in plasma as a biomarker for early
detection of colorectal cancer. Clin Cancer Res. 15:6185–6191.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Richards KL, Zhang B, Sun M, Dong W,
Churchill J, Bachinski LL, Wilson CD, Baggerly KA, Yin G, Hayes DN,
et al: Methylation of the candidate biomarker TCF21 is very
frequent across a spectrum of early-stage nonsmall cell lung
cancers. Cancer. 117:606–617. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jiang D, Hong Q, Shen Y, Xu Y, Zhu H, Li
Y, Xu C, Ouyang G and Duan S: The diagnostic value of DNA
methylation in leukemia: A systematic review and meta-analysis.
PLoS One. 9:e968222014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jiang D, Shen Y, Dai D, Xu Y, Xu C, Zhu H,
Huang T and Duan S: Meta-analyses of methylation markers for
prostate cancer. Tumour Biol. 35:10449–10455. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sui X, Wang D, Geng S, Zhou G, He C and Hu
X: Methylated promoters of genes encoding protocadherins as a new
cancer biomarker family. Mol Biol Rep. 39:1105–1111. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kondo Y and Issa JP: Epigenetic changes in
colorectal cancer. Cancer Metastasis Rev. 23:29–39. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Malhotra P, Anwar M, Kochhar R, Ahmad S,
Vaiphei K and Mahmood S: Promoter methylation and
immunohistochemical expression of hMLH1 and hMSH2 in sporadic
colorectal cancer: A study from India. Tumour Biol. 35:3679–3687.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Pietrantonio F, Perrone F, de Braud F,
Castano A, Maggi C, Bossi I, Gevorgyan A, Biondani P, Pacifici M,
Busico A, et al: Activity of temozolomide in patients with advanced
chemorefractory colorectal cancer and MGMT promoter methylation.
Ann Oncol. 25:404–408. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Herman JG, Merlo A, Mao L, Lapidus RG,
Issa JP, Davidson NE, Sidransky D and Baylin SB: Inactivation of
the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA
methylation in all common human cancers. Cancer Res. 55:4525–4530.
1995.PubMed/NCBI
|
|
46
|
Yagi T: Clustered protocadherin family.
Dev Growth Differ 50 Suppl. 1:S131–S140. 2008. View Article : Google Scholar
|
|
47
|
Reinert T, Modin C, Castano FM, Lamy P,
Wojdacz TK, Hansen LL, Wiuf C, Borre M, Dyrskjot L and Orntoft TF:
Comprehensive genome methylation analysis in bladder cancer:
Identification and validation of novel methylated genes and
application of these as urinary tumor markers. Clin Cancer Res.
17:5582–5592. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tommasi S, Karm DL, Wu X, Yen Y and
Pfeifer GP: Methylation of homeobox genes is a frequent and early
epigenetic event in breast cancer. Breast Cancer Res. 11:R142009.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lin SY, Yeh KT, Chen WT, Chen HC, Chen ST,
Chiou HY and Chang JG: Promoter CpG methylation of tumor suppressor
genes in colorectal cancer and its relationship to clinical
features. Oncol Rep. 11:341–348. 2004.PubMed/NCBI
|
|
50
|
Lind GE, Thorstensen L, Lovig T, Meling
GI, Hamelin R, Rognum TO, Esteller M and Lothe RA: A CpG island
hypermethylation profile of primary colorectal carcinomas and colon
cancer cell lines. Mol Cancer. 3:282004. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Benchimol S, Fuks A, Jothy S, Beauchemin
N, Shirota K and Stanners CP: Carcinoembryonic antigen, a human
tumor marker, functions as an intercellular adhesion molecule.
Cell. 57:327–334. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ding W, Wang J, Wang F, Wang G, Wu Q, Ju
S, Cong H and Wang H: Serum sAPRIL: A potential tumor-associated
biomarker to colorectal cancer. Clin Biochem. 46:1590–1594. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Baek JY, Yeo HY, Chang HJ, Kim KH, Kim SY,
Park JW, Park SC, Choi HS, Kim DY and Oh JH: Serpin B5 is a
CEA-interacting biomarker for colorectal cancer. Int J Cancer.
134:1595–1604. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Petrioli R, Licchetta A, Roviello G,
Pascucci A, Francini E, Bargagli G, Conca R, Miano ST, Marzocca G
and Francini G: CEA and CA19.9 as early predictors of progression
in advanced/metastatic colorectal cancer patients receiving
oxaliplatin-based chemotherapy and bevacizumab. Cancer Invest.
30:65–71. 2012. View Article : Google Scholar : PubMed/NCBI
|
